New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
09:04 EDTSTJSt. Jude Medical enrolls first patient in EnlighHTN II trial for hypertension
St. Jude Medical enrolled the first patient in the EnligHTN II trial. This post-market clinical study will further evaluate the safety and efficacy of the EnligHTN Renal Denervation System in patients with uncontrolled hypertension. The EnligHTN II trial expands upon the research conducted in the EnligHTN I trial, which demonstrated that patients with drug-resistant hypertension treated with the St. Jude Medical EnligHTN system had a rapid and sustained drop in blood pressure. The EnligHTN II study aims to broaden this scope by evaluating the mean reduction in systolic blood pressure at six months across all enrolled patients post renal denervation and within sub-groups with varying degrees of kidney functionality. The study will enroll approximately 500 patients
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:17 EDTSTJSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 14, 2015
09:03 EDTSTJSt. Jude Medical sees Q4 adjusted EPS within $1.02-$1.04 guidance range
Subscribe for More Information
09:02 EDTSTJSt. Jude Medical sees Q4 net sales approximately $1.439B, consensus $1.44B
Subscribe for More Information
09:01 EDTSTJSt. Jude Medical authorizes $500M share repurchase program
The company announced that its board of directors has authorized the repurchase of up to $500M of St. Jude Medical common stock. The repurchases will occur at such times and at such prices as the management of the company determines and may be effected through transactions in the open market, in privately negotiated transactions or otherwise. Any shares acquired in the $500M repurchase program will be available for general corporate purposes, including offsetting dilution associated with stock option and other equity-based employee benefit plans. The company had approximately 287 million shares of common stock outstanding as of Jan. 13, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use